Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 Février 2024 - 2:00PM
Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, will participate in a fireside chat
at the upcoming virtual Oppenheimer 34th Annual Healthcare Life
Sciences Conference on Tuesday, February 13th at 9:20am ET.
A webcast of the presentation can be accessed at the following
link: https://wsw.com/webcast/oppenheimer33/atxs/2815552. An
archived replay of the presentation will be available in the
investors section of www.astriatx.com for 30 days following the
event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206223566/en/
Astria Contact: Investor
Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024